- Home
- ADAP
as 11-15-2024 4:00pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 212.3M | IPO Year: | 2015 |
| Target Price: | $3.16 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.42 - $2.05 | Next Earning Date: | 11-13-2024 |
| Revenue: | $175,041,000 | Revenue Growth: | 146.27% |
| Revenue Growth (this year): | 180.15% | Revenue Growth (next year): | -73.16% |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
BioPharma Dive
2 days ago
Halozyme bids for Evotec; BeiGene gets a new name
Pharmaceutical Technology
3 days ago
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Zacks Small Cap Research
4 days ago
ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027
GuruFocus.com
4 days ago
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...
Newsfile
4 days ago
Adaptimmune Reports Q3 2024 Financial and Business Updates
Newsfile
4 days ago
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Newsfile
12 days ago
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.